Mehul S Patel1, Divya Mohan1, Yvonne M Andersson2, Manuel Baz1, S C Samantha Kon3, Jane L Canavan3, Sonya G Jackson2, Amy L Clark4, Nicholas S Hopkinson1, Samantha A Natanek1, Paul R Kemp5, Piet L B Bruijnzeel2, William D-C Man4, Michael I Polkey6. 1. NIHR Respiratory Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust and Imperial College London, London, England. 2. Respiratory, Inflammation, and Autoimmune Diseases, AstraZeneca, Mölndal, Sweden. 3. NIHR Respiratory Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust and Imperial College London, London, England; Harefield Pulmonary Rehabilitation Unit, London, England. 4. Harefield Pulmonary Rehabilitation Unit, London, England. 5. Department of Molecular Medicine, Imperial College London, London, England. 6. NIHR Respiratory Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust and Imperial College London, London, England. Electronic address: m.polkey@rbht.nhs.uk.
Abstract
BACKGROUND: The Short Physical Performance Battery (SPPB) is commonly used in gerontology, but its determinants have not been previously evaluated in COPD. In particular, it is unknown whether pulmonary aspects of COPD would limit the value of SPPB as an assessment tool of lower limb function. METHODS: In 109 patients with COPD, we measured SPPB score, spirometry, 6-min walk distance, quadriceps strength, rectus femoris cross-sectional area, fat-free mass, physical activity, health status, and Medical Research Council dyspnea score. In a subset of 31 patients with COPD, a vastus lateralis biopsy was performed, and the biopsy specimen was examined to evaluate the structural muscle characteristics associated with SPPB score. The phenotypic characteristics of patients stratified according to SPPB were determined. RESULTS: Quadriceps strength and 6-min walk distance were the only independent predictors of SPPB score in a multivariate regression model. Furthermore, while age, dyspnea, and health status were also univariate predictors of SPPB score, FEV 1 was not. Stratification by reduced SPPB score identified patients with locomotor muscle atrophy and increasing impairment in strength, exercise capacity, and daily physical activity. Patients with mild or major impairment defined as an SPPB score < 10 had a higher proportion of type 2 fibers (71% [14] vs 58% [15], P = .04). CONCLUSIONS: The SPPB is a valid and simple assessment tool that may detect a phenotype with functional impairment, loss of muscle mass, and structural muscle abnormality in stable patients with COPD.
BACKGROUND: The Short Physical Performance Battery (SPPB) is commonly used in gerontology, but its determinants have not been previously evaluated in COPD. In particular, it is unknown whether pulmonary aspects of COPD would limit the value of SPPB as an assessment tool of lower limb function. METHODS: In 109 patients with COPD, we measured SPPB score, spirometry, 6-min walk distance, quadriceps strength, rectus femoris cross-sectional area, fat-free mass, physical activity, health status, and Medical Research Council dyspnea score. In a subset of 31 patients with COPD, a vastus lateralis biopsy was performed, and the biopsy specimen was examined to evaluate the structural muscle characteristics associated with SPPB score. The phenotypic characteristics of patients stratified according to SPPB were determined. RESULTS: Quadriceps strength and 6-min walk distance were the only independent predictors of SPPB score in a multivariate regression model. Furthermore, while age, dyspnea, and health status were also univariate predictors of SPPB score, FEV 1 was not. Stratification by reduced SPPB score identified patients with locomotor muscle atrophy and increasing impairment in strength, exercise capacity, and daily physical activity. Patients with mild or major impairment defined as an SPPB score < 10 had a higher proportion of type 2 fibers (71% [14] vs 58% [15], P = .04). CONCLUSIONS: The SPPB is a valid and simple assessment tool that may detect a phenotype with functional impairment, loss of muscle mass, and structural muscle abnormality in stable patients with COPD.
Authors: Sara C Buttery; Divya Mohan; Marie Fisk; Nicholas S Hopkinson; Ruth Tal-Singer; Ian B Wilkinson; Michael I Polkey Journal: Eur Respir J Date: 2017-08-10 Impact factor: 16.671
Authors: Rafaella F Xavier; Ana Carolina A C Pereira; Aline C Lopes; Vinícius Cavalheri; Regina M C Pinto; Alberto Cukier; Ercy M C Ramos; Celso R F Carvalho Journal: Lung Date: 2018-11-14 Impact factor: 2.584
Authors: Rosanne J H C G Beijers; Bram van den Borst; Anne B Newman; Sachin Yende; Stephen B Kritchevsky; Patricia A Cassano; Douglas C Bauer; Tamara B Harris; Annemie M W J Schols Journal: J Am Med Dir Assoc Date: 2016-02-23 Impact factor: 4.669
Authors: Mehul S Patel; Samantha A Natanek; Grigorios Stratakos; Sergi Pascual; Juana Martínez-Llorens; Laura Disano; Gerasimos Terzis; Nicholas S Hopkinson; Joaquim Gea; Ioannis Vogiatzis; François Maltais; Michael I Polkey Journal: Am J Respir Crit Care Med Date: 2014-08-01 Impact factor: 21.405
Authors: Raolat M Abdulai; Tina Jellesmark Jensen; Naimish R Patel; Michael I Polkey; Paul Jansson; Bartolomé R Celli; Stephen I Rennard Journal: Am J Respir Crit Care Med Date: 2018-02-15 Impact factor: 21.405
Authors: Divya Mohan; Victoria S Benson; Matthew Allinder; Nicholas Galwey; Charlotte E Bolton; John R Cockcroft; William MacNee; Ian B Wilkinson; Ruth Tal-Singer; Michael I Polkey Journal: Chronic Obstr Pulm Dis Date: 2020-01